Adam S. Kibel, MD is Chief of Urologic Surgery at both the Brigham & Women’s Hospital and Dana-Farber Cancer Institute in Boston, Massachusetts. In addition, he is the Elliott Carr Cutler Professor of Surgery at Harvard Medicine School, Chairman of the Harvard Program in Urology Residency Program and Co-Leader of the Prostate Cancer Program for Dana Farber/Harvard Cancer Center. Dr Kibel received his undergraduate and medical degrees from Cornell University, completed his urology residency at the Harvard Urology Program, and his fellowship in Urologic Oncology at the Brady Urologic Institute at Johns Hopkins in Baltimore, Maryland.
With a practice focused on minimally invasive treatments for urologic cancers, Dr. Kibel has been listed as one of America’s Top Doctors by Castle Connolly. The author of over 250 peer-reviewed publications, Dr Kibel’s research focuses on the identification of molecular markers of urologic tumors, integration of systemic agents earlier in the disease process and improved imaging of patients with urologic malignancies. His research has been supported by the National Cancer Institute, American Cancer Society, American College of Surgeons, and the American Foundation for Urologic Disease."
Fred Saad MD FRCS, is Full Professor, Chairman of Urology and Director of Genitourinary Oncology at the University of Montreal Hospital Centers (CHUM). He holds the U of M Endowed Chair in Prostate Cancer Research and is Director of the molecular oncology research lab in Prostate Cancer.
He is also Director of clinical cancer research at the CHUM research center (CRCHUM). Dr Saad is Lead Investigator of the Canadian Prostate Cancer Biomarker Network and a principal investigator with the Movember bio-marker initiatives in prostate cancer. He has published over 300 articles in many prestigious journals such as The New England Journal of Medicine, Lancet, JCO and JNCI. He sits on 7 editorial boards and is a reviewer for over 30 scientific journals. Dr Saad’s research interests include molecular prognostic markers, mechanisms of progression and new therapeutics in prostate cancer. He has over 40 clinical and basic research projects ongoing.
Chawn Shang Chang
Dr. Chang’s research focuses on the Androgen Receptor (AR). His pioneer cloning of human and rat Androgen Receptor (Science-1988) represents the landmark discovery in the androgen-AR field that not only lead to identify the pathogenesis of Testicular Feminization Syndrome and SBMA Neuron Diseases, but also allows Urologists for the first time to monitor the AR status of processing prostate cancer and dissect the mechanisms for failure of androgen deprivation therapy. Dr. Chang then discovered the first AR co-regulator (1996-PNAS) that lead to subsequent findings of more than 100 such co-regulators and their function in the modulation of Androgen-AR functions in various diseases. In 2002 Dr. Chang’s lab generated the first floxed AR mouse (PNAS-2002) that deleted AR in a selective cell and identify the first compound (ASC-J9) that selectively degraded AR in selective cells, that led to the development of first potential therapy to selectively target AR in SBMA Neuro disease (Nature Medicine-2007), Neutropenia (JEM-2009), bladder cancer (JNCI-2007), wound healing (JCI-2009) and hepatitis B-induced liver cancer (Science-TM-2010).
By knockout AR in individual cell of prostate, Dr. Chang’s lab then discovered AR could function as suppressor to CK5-basal intermediate epithelial cell, as survivor to CK-8 luminal epithelial cell and as proliferator to stromal cell. These findings of differential AR function in individual cells of prostate not only help to explain why androgen deprivation therapy via systematic suppression androgen would fail, it also helps to develop new drugs to target AR in selective prostate cell to battle prostate cancer. Dr. Chang is founder of AndroScience Corporation established at 2001. Dr. Chang published 460 papers with citation over 32,000 in the AR-Urology/Oncology/Endocrinology field and trained more than 200 Ph.D. students/post Drs.; 70 of his trainees are now professors in various Universities.
Kyu-Sung Lee is Professor of Urology and General Director in the Smart Health Care & Medical Device Research Center at Samsung Medical Center in Seoul, Korea. He is chairman of Department of Urology, Samsung Medical Center. Prof Lee completed his undergraduate training at Seoul National University College of Medicine, where he also underwent postgraduate training, specializing in urology. He previous worked as a Clinical and Research Fellow of Urology at Samsung Medical Center, and completed a PhD (Urology) at Seoul National University College of Medicine. Prof Lee has held previous positions as a Visiting Professor of Urology at both the University of Virginia School of Medicine in Virginia, US, and the University of California San Diego, in California, US.
He is a member of numerous professional organizations including the Korean Urological Association, Korean Continence Society, American Urological Association, International Uro-gynecology Association, International Continence Society, European Association of Urology and Urological Association of Asia. He is the editorial board for the International Neurourology Journal, Investig Clin Urol, and LUTS. He is president-elect of Korean Urological Association To date, Prof Lee has contributed more than 150 peer-reviewed articles to the international scientific journal and urological communities, and has presented the results of his studies both nationally and internationally. His current research interests include optogenetics and neuromodulation in the field of bladder outlet obstruction, neurogenic bladder dysfunction, urinary incontinence, and overactive bladder."
Membership of academic societies:
Japanese Urological Association (JUA): Board of Director (2017-present, Chief of Health insurance section) (2015-2017, Chief of BPH & Geriatric Urology section) (2010-2014, Chief of Female Urology section)
Japanese Continence Society: Board of Director Japanese Society of Female Pelvic Floor Medicine: Board of Director (Vice Chairman)
Japanese Association for Cancer Detection and Diagnosis: Board of Director Japanese Geriatric Urological Association: Board of Director (Vice Chairman) AUA, EAU, ICS, IUGA (member of Research and Development Committee)
Research Fields: Voiding dysfunction, Urogynecology, Urologic Oncology "
Jim C. Hu
Jim C. Hu
Dr. Jim Hu is a urologic oncologist, with his undergraduate degree in Economics, his Masters in Public Health in Health Policy and Management from Johns Hopkins University and his Medical Degree from Baylor College of Medicine. He completed his Urology Residency at the David Geffen School of Medicine at UCLA and his Urologic Oncology Fellowship at City of Hope National Medical Center.
He began his career as the Director of Robotic and Minimally Invasive Surgery at Brigham and Women's Hospital and Instructor at Harvard Medical School and was quickly promoted to Director of the Prostate Cancer Program at Dana Farber/Harvard Cancer Center and Associate Professor. He was then recruited back to UCLA as the Henry Singleton Chair of Robotic and Minimally Invasive Surgery and was promoted to Professor before joining the faculty at Weill Cornell Medical College as the Director of the LeFrak Center for Robotic Surgery and the Ronald P. Lynch Chair in Urologic Oncology.
Dr. Hu is internationally renown as a surgical innovator and health services researcher. His comparative effectiveness research interests have been funded by the Department of Defense, National Cancer Institute and the Livestrong Foundation, and his areas of clinical and research expertise include prostate and kidney cancer. He has authored more than 150 peer-reviewed papers. Dr. Hu has performed thousands of robot-assisted prostatectomies, among over 3500 laparoscopic, robotic and open procedures.
Axel S. Merseburger
Prof Axel S. Merseburger is currently Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany, having previously served as Vice Chairman of the Department of Urologic Oncology and Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Professor Merseburger obtained his medical degree from Hannover Medical School in 2002 following a 1-year academic research programme in Washington D.C., USA, where he finished his M.D. thesis. He completed a residency in surgery and urology at the Eberhard Karls University in Tübingen, Germany, and was a Research Fellow at the Miller School of Medicine, Miami, USA, in 2006.
Professor Merseburger accepted a position as a staff member in Hannover in 2008 and was promoted to Associate Professor in 2009 and full Professor in 2012. Professor Merseburger is board certified in urology and is a member of numerous national and international urological and oncological associations, as well as serving as a reviewer and member of the editorial board for many journals, Professor Merseburger is Associate Editor of the World Journal of Urology.
Furthermore, he is a member of the European Association of Urology (EAU) Guideline Group for Renal Cancer and Chairman of the EAU Guideline Group for Lasers and Technologies. Professor Merseburger has won multiple awards, stipends and prizes for his molecular and clinical research and has published more than 150 papers in peer-reviewed journals. His main area of interest is urological oncology. Professor Merseburger’s key areas of interest are renal cell carcinoma, prostate cancer and transitional cell carcinoma, with special attention given to novel markers and prognostic factors. He is a principal investigator in German Phase II and III trials.
Antonio Alcaraz Asensio
Antonio Alcaraz Asensio
I was trained mainly at the University of Barcelona. My mentors were Prof. Gil-Vernet, world-wide recognize urologist and Prof. Talbot-Wright, vascular surgeon and urologist. After my stay in the United States, I focused in uro-oncology taking to Spain the Mayo Clinic techniques. However, kidney transplant techniques were superior in Barcelona, so we continue to refine them.
Always maintaining my surgical activity in bladder and prostate cancer (including robotics) I was progressively focusing in kidney surgery, moving from open surgery to laparoscopy in 2002 at Fundacio Puigvert. In the last years, we are considered as one of the pioneers in transvaginal and single port kidney surgery. So far, I have performed more than four thousand kidney surgeries, two thirds of them on laparoscopy. As well, more than five hundred living donor nephrectomies including one hundred and twenty transvaginal and more than one thousand kidney transplants as a surgeon. However, our work it is always considered as a team work. At least two people should be able to perform any surgical procedure. I consider myself to be very lucky to work with my young staff, grown professionally under my direction.
Jean de la Rosette
Jean de la Rosette
Dr de la Rosette is Professor in Urology at AMC University Hospital in Amsterdam (the Netherlands) and Professor in Urology at Istanbul Medipol University, Istanbul (Turkey). He completed his medical degree and urology residency at St Radboud University Hospital in Nijmegen, the Netherlands. His main fields of interest are minimal invasive surgery and endourology with a special focus on ablative treatments and urological ultrasound.
Dr de la Rosette is a member of the committee on Minimal Invasive Treatment of Benign Prostatic Hyperplasia (BPH) and the committee on Upper Urinary Tract Urothelial tumors of the ICUD. He is also co-chairman of the committee on Renal Stone Disease of the ICUD. He is past-chairman of the EAU Section of Uro-Technology (ESUT) and board member of the Society of Endourology.
Dr. de la Rosette was a chairman of the European Association of Urology (EAU) working party on BPH guidelines. Dr de la Rosette is (co)author of over 700 peer-reviewed publications and has authored many book chapters. Dr de la Rosette is a member of various urological societies and board member of the Endourological Society and the Société International d’Urologie (SIU). Since 2016 he holds the position of General Secretary of the SIU.
Professor Masato Fujisawa is now in charge of President of Japanese Urological association, Vice President of Japanese society of Endourology and President of Japanese society of Andrology. Prof. Fujisawa has been focusing on endourology, especially robotic surgery, Urooncology, Andrology, Renal transplantation. So far he has already published more than 500 peer-reviewed articles to the international scientific journal and urological communities. He has been executing a clinical trial of robotic partial nephrectomy especially for hilar tumor in Japan.
Also, his team has been collaborating with Medicaroid to make a new surgical robot in Japan.
Syed A. Hussain
Syed A. Hussain
I have been closely involved in the teaching of my junior colleagues in clinics, hospital and ward rounds. I also held Primary Supervision of 1 PhD and 2 MRes students whilst at the University of Liverpool. In addition I co-supervised 4 PhD students at the University of Liverpool. I regularly taught on the National Cancer Research Network (NCRN) courses. I have also been the primary tutor supervising medical students at the University of Liverpool, undertaking research projects.
I was academic supervisor for 5 students at the University of Liverpool. In addition, I taught on the clinical pharmacology module for the MRes students at the University of Liverpool where I also did the marking for this course. I also gained experience through regularly teaching on the registrar training and teaching program.
Sustained excellence in design and delivery of L&T, including evidence of innovation, I regularly teach the medical students and postgraduate trainees in oncology. This includes a specialist registrar attached to my firm. I am also involved in teaching for the regional SPR Training Programme. I was academic supervisor for 5 postgraduate students.
Teaching rooted in up-to-date engagement with developments in discipline
I am a regular attendee at scientific and clinical meetings as a speaker and as a delegate. I also take GCP courses as a prerequisite to act as a chief investigator. The information and understanding gained is transferred to students through my formal and informal lectures in the day-to-day clinic settings.
Leading the development of enhancements to the curriculum and broader student experience
I regularly taught undergraduate and postgraduate medical students as a part of the pharmacology module at the University of Liverpool. Provision of academic guidance and support to students, in areas including employability, disability, accessibility etc, and active support for key events (e.g. invigilation) I regularly see and advise medical students and oncology trainees regarding projects, research and opportunities.
I love using cutting edge science to improve the outcomes for cancer patients that I see each day in clinic. Every day is different as technology and treatment evolves. In partnership with laboratory scientists, I work with a team focused on harnessing these changes.
My main areas of clinical responsibility is the management of patients with genitourinary cancer and involvement in clinical trials in this patient population. I also work in drug development and phases of clinical trials.
My translational cancer research interests involve the optimisation of immunotherapy and precision medicine. This involves the identification of novel targets, refinement of biomarker assays, monitoring and evaluation of therapeutic response to therapy, and identification of resistance mechanisms to therapy. I design clinical trials – aiming to improve on standard therapies with new drugs. I analyse patient clinical outcomes and match the results of the trial to profiles of patient’s immune cells and cancer cells to identify how to predict which patients may benefit the most from these types of treatment in the future.
My aim is to try and find the right combination of immune therapy or targeted therapy for the right patient so that durable control of cancer can be achieved with minimal side effects. My work has appeared in publications such as the New England Journal of Medicine, Journal of Clinical Oncology, Cancer, Clinical Cancer Research and the British Journal of Cancer.
Brian K. Lee
Brian K. Lee
The UCSF Connie Frank Transplant Center is a major transplant center in the West of United States. Evaluates over 1,000 patients a year as potential transplant candidates, approximately 6000 kidney transplant recipients regularly follow up and performs more than 325 transplants a year.
Dr. Brain Lee take care over 70 kidney transplant new patients per year and also Medical Director of Living Kidney Donation Program, UCSF – Primary advocate for living kidney donors.
Program Director of Transplant Nephrology Fellowship Program, UCSF –Responsible for the recruitment, schedule, educational program and mentoring of transplant nephrology fellows
Director of Kidney Transplant Outreach Program, UCSF – Strategizing and coordination of efforts to increase visibility and marketing of the kidney transplant program in the North California area.
Attending, Kidney Transplant Unit, UCSF – Inpatient attending physician on average once per month supervising house staff, nephrology and transplant nephrology fellows. Kidney Transplant Recipient Evaluations, UCSF.
Non-Renal Solid Organ Transplant Consult Service, UCSF – Attending physician for both the inpatient and outpatient consultative services, evaluating patients with non-renal solid organ transplants with renal dysfunction.
Post-Kidney Transplant Clinic, UCSF – Attending physician on the twice-weekly routine follow-up clinic for kidney transplant recipients, managing both medical and surgical aspects of care.
Anthony Chi-Fai Ng
Anthony Chi-Fai Ng 吳志輝
"Dr NG Chi Fai, Anthony graduated in the Chinese university of Hong Kong in 1993. He then joined Department of Surgery, Prince of Wales Hospital, as surgical trainee. After his basic training, he decided to become an urologist and became a specialist in 2001. Attracted by the rapid development in endourology, he spent one year in Scotland, worked under Mr David Tolley, and gained extensive experience in endo-laparoscopic surgery and stone management.
After completion of his training, Dr Ng decided to join the Chinese University of Hong Kong in 2006 and is currently Director and Professor of the S.H. Ho Urology Centre, Department of Surgery, the Chinese University of Hong Kong. He is also the Course Director of the Robotic Surgery Training Programme, CUHK Hong Kong Jockey Club Minimally Invasive Surgical Skill Centre. He has a wide range of interest, in particular in prostate diseases, urolithiasis, and promotion of men’s health. He was also honored with the Outstanding Young Urologist Award in 2010 by the Asian Congress of Urology, the International Guest Scholar 2012 of the American College of Surgeons and the World Chinese Urology Association Award 2014, as recognitions to his work in the field."
Lap-Hong Ian 甄立雄
President, Macau Urological Association
C.H.C.S.J. Macau Consultant Urologist
"Dr. Egawa is a senior Professor and Chairman of the Department of Urology at Jikei University School of Medicine, who also serves as Director of the Asian School of Urology of the Urological Association of Asia, is an authority on prostate cancer.
In April 2004, Prof. Egawa was appointed the 6th chairman and professor of urology at Jikei University School of Medicine, the oldest department in Japan. Under Professor Egawa’s leadership, the department has now 81 members (including 40 residents) serving at the Jikei University Hospital, three attached hospitals, and 15 affiliated hospitals."
"Dr Rajeev Kumar is Professor of Urology and Associate Dean for Academics at the All India Institute of Medical Sciences, New Delhi, India where he obtained all his medical training and graduated at the top of his class both for the basic and urology degrees.
His principal areas of clinical work are microsurgery, laparoscopy and robotics. His research interests focus on genetics of male infertility and magnetic resonance techniques for prostate cancer. He has published over 200 articles and book chapters. He has an interest in Journalology and conducts workshops, internationally, on medical writing and research methodologies.
He is Chief Editor of the Indian Journal of Urology and serves in various editorial capacities for the Journal of Urology, National Medical Journal of India, International Journal of Urology, Korean Journal of Urology, Asian Journal of Urology, and the Journal of Men's Health. He is Secretary of the World Association of Medical Editors and serves as a co-opted executive committee member of the Urological Association of Asia by virtue of being chairman of its young urologists’ section and editor of its newsletter. He is a member of the National Academy of Medical Sciences of India.
"David Winkle is a urological surgeon treating adult and paediatric patients.
He is a consultant urologist at the Mater Adult Hospital, the Lady Cilento Childrens Hospital (LCCH) and at a number of private hospitals in Brisbane ,Australia. Dr Winkle has extensive experience in the fields of urological reconstruction, paediatric urology, bladder dysfunction and urinary stone disease.
He has worked as a urologic surgeon for over three decades.
Dr Winkle is a graduate from the University of Queensland and obtained his initial surgical and urological training in Queensland.
As the Australian Travelling Fellow in Urology, he studied and worked in the United Kingdom at the Institute of Urology in London and at the Bristol Hospital for Sick Children. He is an examiner for the Royal Australasian College of Surgeons.
Dr Winkle is a Senior Lecturer at University of Queensland. He has been an invited lecturer to numerous national and international meetings and has publications in the fields of paediatric and urologic reconstruction.
Dr Winkle was the President of the Urological Society of Australia and New Zealand from 2013 to 2015. He is the Chairman of the International Committee of the Urological Association of Asia and holds positions in a number of national and international professional bodies."
Dato Dr Rohan Malek is the Senior Consultant Urologist and Head of Department of Urology, Selayang Hospital, Selangor, Malaysia. He is appointed as the National Head for Urology, Ministry of Health, Malaysia. Dr Rohan Malek graduated with MBBS from Monash University, Australia. Initially, he underwent training as a general surgeon and obtained his FRCS from RCS Edinburgh and RCPS Glasgow in 1993. He later underwent Urology specialty training at the Department of Urology, Kuala Lumpur Hospital from 1993-1996 followed by a 1year Fellowship in the United Kingdom. He obtained the Diploma in Urology from University College London in 1997 and is a Fellow of the European Board of Urology since 2004. He has now been practising as a Consultant Urologist and Renal Transplant surgeon for the past 21 years. As Chairman of the Malaysian Board of Urology, he is also very much involved in the training of Malaysian Urologists through the Malaysian Board of Urology programme. Dr Rohan Malek was the President of the Malaysian Urological Association(MUA) from 2004-2008 and is the present Honorary Treasurer of MUA. He is the organising Chairman for the 17th UAA Congress to be held in Kuala Lumpur in 2019 and has recently been elected as the President Elect of the Urological Association of Asia (UAA).
"A Head of the Department of Urology of the University Medical Centre of Hochiminh City Vietnam, Dr. Nguyen H. Duc’s special interests include cancer of
the urinary tract, urinary stone diseases and minimally invasive surgery in Urology. Dr. Nguyen completed his medical education in 1998 at the University of
Medicine of Hochiminh City, Vietnam and then completed a rotating residency and clinical fellowship in Vietnam as well as in some well-known Institutes in
South East Asia, United Kingdom, France and the United States of America. He also holds a Diploma in laparoscopic surgery from Louis Pasteur Unviversity in
Dr Nguyen has presented at numerous seminars on Endourology in Asia. He is currently a member of many professional organizations at both Vietnam and
overseas. He is also a co-author of two books on Endourology and Laparoscopic Urological Operations published in Vietnam."
Nizar M. Tannir, MD, FACP, is Professor and Deputy Chair in the Department of Genitourinary Medical Oncology at MD Anderson Cancer Center, and is a clinical investigator with expertise in trial design. Dr. Tannir has conducted numerous clinical trials in renal cell carcinoma (RCC), and is an expert on rare kidney cancers, including translocation RCC (tRCC), renal medullary carcinoma (RMC), and collecting duct carcinoma. He co-chairs a think-tank on RMC, bringing together world experts from different fields to accelerate discovery and novel therapeutics for this devastating orphan cancer.
Dr. Tannir has authored and co-authored more than 215 original manuscripts and several book chapters. He is editor of Renal Cell Carcinoma, a book published by Oxford University Press in 2014.
Dr. Tannir co-chairs a yearly urological oncology symposium at MDACC, and serves on the scientific and medical advisory board of the Kidney Cancer Association.
Dr. Tannir’s translational research is focused on deciphering the molecular underpinnings of RMC and tRCC. He is Principal Investigator of several clinical trials in advanced clear-cell and non-clear cell RCC, including rare variants, with emphasis on identification of prognostic and predictive biomarkers.
Dr. Tannir was voted Teacher of The Year five times, and received numerous awards including the 2013 Gerald P. Bodey Award for Excellence in Education, the 2014 Waun Ki Hong Award for Leadership in Education, the 2014 Melvin L. Samuels Award for Excellence in Patient Care, the 2016 UT Cancer Foundation Faculty Achievement Award in Patient Care, and the 2017 Eugene P. Schonfeld Award from the Kidney Cancer Association.
Dr. Park is Korean board-certified prosthetic urologist. He is clinical associate professor of Ajou university, Suwon, Korea, chief surgeon of Sewum Prosthetic Urology Center of Excellence and leading researcher of Wilson Memorial Research & Training Center for Penile Prosthetic Surgery. After his residency, he went to US and completed multicenter prosthetic urology training under the guidance of Steven K. Wilson MD, FACS, FRCS. His most notable researches are about IPP under local anesthesia and he has been invited to ESSM Lisbon 2018 for semi-live surgery course under the title of “Subcoronal IPP under local anesthesia.”. Currently, he is one of the highest volume inflatable penile prosthesis implanter in the world.
"I continue to deliver comprehensive care for patients with urinary stone disease. I have initiated involvement with endocrinology and nephrology fellows that rotate through my clinic. This gives them visibility to these unique patients with emphasis on pre- and post-operative care, and complete metabolic evaluations to help reduce stone recurrence. This has culminated in the publication of a comprehensive textbook on urinary stone disease that I edited. I also have initiated bringing in groups of patients with similar diseases such as cystinurics. This allows me to give them educational materials and inform them of the latest advancements. It gives them a unique support group to help cope with this chronic ailment.
I have expanded the minimally invasive approach to the kidney and have refined the laparoscopic approach to both extirpative and reconstructive laparoscopy. I have continued to help develop and assess new laparoscopic instrumentation and techniques. I have also refined my percutaneous approach to the kidney to remove large urinary stones - especially in the morbidly obese patients.
Peggy Sau-Kwan Chu
Peggy Sau-Kwan Chu 朱秀群
Dr Peggy CHU is the consultant urologist in Tuen Mun Hospital and the past president of the Hong Kong Urological Association, 2010-2012.
Dr CHU received her medical degree from the University of Hong Kong. She then received her urology training from Queen Elizabeth Hospital. Her overseas training took place at the Institute of Urology, University College London, in 1996. After coming back from London, she continued to work in Queen Elizabeth Hospital until 2006; since then she continued her career in Tuen Mun Hospital.
Dr Peggy CHU is specialized in reconstructive, neuro and female urology. She led the team, including urologists from Princess Margaret Hospital and toxicologists from United Christian Hospital, which reported the first 10 cases in Hong Kong with contracted bladder and upper urinary tract damage associated with ketamine abuse. This discovery has raised the Hong Kong Government’s and the community’s awareness of the social problems associated with Ketamine abuse. She also provided an affidavit to the Hong Kong High Court, thus leading to more stringent guidelines on sentencing of ketamine abuse since June 2008. Dr CHU received the Outstanding Staff Award from Hong Kong Hospital Authority in 2009.
Dr CHU had been the member of the executive board of British Journal of Urology International since 2011.
E. David Crawford
E. David Crawford
E. David Crawford is an internationally renowned urologist and is the distinguished endowed Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles.
Dr. Crawford is an internationally-recognized expert in benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer. He has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 616 scientific articles, has published seven textbooks and authored over 50 book chapters. Dr Crawford is also an editorial reviewer or consultant for many publications, including Urology, Journal of Urology, The New England Journal of Medicine, Cancer, JAMA and the Journal of Clinical Oncology."
Urology Department Urology
Areas of interest
Laser prostate surgery
Robotic radical prostatectomy
Complex kidney stones
Robotic and laparoscopic kidney stones"
Jin Chun Xing
Jin Chun Xing 邢金春
專長：在泌尿系腫瘤、泌尿系結石的外科手術及綜合診療方面有較深造詣，致力於微創腔內手術技術的創新、引進、推廣和運用。成就：獲得“中華醫學會泌尿外科學分會（CUA）2012 年度鑽石獎”、“中華醫學會泌尿外科學分會（CUA）2016 年度女媧獎”，完成省級科技進步獎三等獎2 項、市級科技進步獎一等獎1 項、市級科技進步獎二等獎2 項、市級科技進步獎三等獎2 項。以第一承擔人獲得省科技廳重點項目2 項、省衛生教育聯合攻關計畫1 項、市衛生局重點項目12 項、高校合作項目6 項。獲國家實用新型專利6 項。
以第一或通訊作者發表國內外核心期刊百餘篇，其中SCI 23 篇。主編《前列腺癌診斷治療學》，副主編《泌尿系結石臨床診斷治療學》和《膀胱切除與尿流改道手術學》，參編《泌尿系結石》、《內鏡微創學》（全國高等醫藥院校教材）、
《婦幼泌尿外科學》、《泌尿系結石》（第二版）、《辛曼泌尿外科手術圖解》（譯著）、《外科學：泌尿外科分冊》（衛計委住院醫師規範化培訓規範教材）、《泌尿外科手術併發症的預防和處理》（譯著）。副主編《泌尿系統其他疾病診斷治療指南》（2011 版）、《精索靜脈曲張診斷治療指南》（2011 版）、《輸尿管結石診斷治療指
南》（2013 版），參編《中國鹿角型結石診療指南》（2009 版）、《鹿角型腎結石診斷治療指南》（2011 版）。"
Wei Zhang 張煒
Bin Chen 陳斌
3、 海峽兩岸醫藥衛生交流協會第三屆理事 、泌尿外科專業委員會委員兼總幹事長
Xin Gou 苟欣
De Gang Ding
Degang Ding 丁德剛
丁德剛 科主任 醫學博士 碩導 教授
Yao Guang Zhang
Yao Guang Zhang 張耀光
兼任中華醫學會泌尿外科分會（CUA）青年委員會副主任委員、 CUA尿控學組秘書、 CUA女性泌尿外科學組委員、中國醫師學會神經調控委員會委員、北京市尿控學組副組長； 《中華泌尿外科雜誌》、 《現代泌尿外科雜誌》、 《泌尿外科雜誌（電子版）》 編委（或通訊編委）等職務。
Zi Chen Zhao
Zi Chen Zhao 趙子臣
北京大學首鋼醫院。北京⼤大學吳階平泌尿外科醫學中心 | 泌尿外科主治醫師
北京⼤大學首鋼醫院 · 醫療模擬培訓中心 | 副主任
美國外科醫師學院(ACS) | 醫療模擬教育研究員
Kin Li 李堅
Xiao-Xin Meng 孟小鑫
Area of Interests:
Yue Cheng 程躍
Area of Interests:
Dong Wei 魏東